PharmacyCan you imagine a world where the new norm required insurers and providers to disclose what they charge upfront? Read as Mark Gaunya, president of the Massachusetts Association of Health Underwriters, shares two specific messages he took to the Hill at the Cap Conference and the outcome.
A national coalition of pharmacists and pharmacy owners announced last week a public information campaign to expose the unjustifiably high prices of prescription drugs set by pharmacy benefit managers, the unregulated, multibillion dollar industry that controls prescription health plans for more than 200 million Americans.
Twenty-five percent of employers have little or no understanding of specialty pharmacy and 53% have only a moderate understanding of this challenging benefit according to a new survey released by the Midwest Business Group on Health.
Pharmacy-related wasteful spending topped $403 billion in 2010, up from $163 billion in 2009, according to the 2010 Drug Trends Report by Express Scripts. Between 2010 and 2014, estimates put the figure at more than $1.2 trillion.
UnitedHealth Group is pushing into managing pharmacy benefits, bucking a trend among U.S. health insurers and threatening the dominance of the three largest companies that help negotiate drug pricing.
Medco Health Solutions Inc. will lose a major pharmacy benefit contract to CVS Caremark Corp. starting next year, sending Medco shares down almost 11% and CVS up nearly 4% Friday.
Expensive new cancer drugs, treating increasing numbers of patients, could drive up cancer drug spending by as much as 15% a year through 2013, according to the newly released 2011 Medco Drug Trend Report, which tracks drug utilization and spending.
Jennifer Kingsley Wilson, CEO of pharmacy benefit management consultancy ARMSRx, breaks down where the PBM industry stands after a tumultuous 2010. From contract changes to AWP, Wilson shares and why it's important for you to keep your clients in the know.
Catalyst Health Solutions Inc said it will buy Walgreen Co's pharmacy benefits management unit for about $525 million in cash, a deal that might spur more consolidation before big generic drug launches that could boost the business.